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Abstract
The paper presents a critical review (with search date 2010) of the major psychotropic medications
assessed in eating disorders, namely antipsychotics, antidepressants, mood-stabilizing medications,
anxiolytic and other agents. The evidence of eﬃcacy of drug treatments is mostly weak or moderate.
In addition, attrition rates are usually higher than for psychotherapies. However, there is support for use
of antidepressants, particularly high-dose ﬂuoxetine in bulimia nervosa, and anticonvulsants (topiramate)
for binge-eating disorder. Low-dose antipsychotic medication may be clinically useful as adjunct
treatment in acute anorexia, particularly where there is high anxiety and obsessive eating-related rumi-
nations and failure to engage, but more trials are needed. Drug therapies such as topiramate and
anti-obesity medication may aid weight loss in obese or overweight patients with binge-eating disorder ;
however, common or potentially serious adverse eﬀects limit their use.
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Introduction
Eating disorders comprise anorexia nervosa, bulimia
nervosa, binge-eating disorder (BED) and eating dis-
order not otherwise speciﬁed (EDNOS) (APA, 2000).
Lifetime prevalence estimates in the community are
0.6% for are anorexia nervosa, 1.0% for bulimia
nervosa, and 2.8% for BED (Hudson et al. 2007). Both
birth-cohort estimates (Hudson et al. 2007) and
sequential population surveys (Hay et al. 2008) suggest
an increase in disorders of recurrent binge eating in
recent years. Eating disorders are characterized by
disordered eating behaviours together with cognitive
schema of self-view being unduly inﬂuenced by body
image or weight and shape concerns and extreme
preoccupation with thoughts of food and eating (APA,
2000). Disordered eating behaviours include binge
eating (uncontrolled eating of inappropriately large
amounts of food), subjective binging on smaller
food quantities, severe dietary restriction, and weight
control behaviours such as vomiting, use of diuretics
or laxatives and driven exercise. The latter behaviours
are also used as compensation for the recurrent binge
eating typical of bulimia nervosa. In BED there is
similar recurrent overeating without compensation.
All eating disorders have known physical as well as
psychological morbidity. People with anorexia nervo-
sa are distinct in being underweight and hence in a
starvation state. In the clinic obesity is extremely
common in patients with BED and in community
surveys (e.g. Hudson et al. 2007) over 40% with BED
are obese with body mass index (BMI) >30. Those
with BED may also be at increased risk of metabolic
syndrome over and above risk due to obesity alone
(Hudson et al. 2010). Other non-speciﬁc psychiatric
features such as anxiety or mood disturbance, ob-
sessionality and impulsivity are also common.
Treatments are thereby multi-dimensional comprising
psychotherapy, nutritional rehabilitation, sometimes
medical resuscitation and the judicious use of
psychotropic and other medication (Treasure et al.
2010).
The present paper reviews the use of psycho-
pharmacological agents in eating disorders. The focus
of research (and hence this review) has been on the
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three well-described diagnostic groups of anorexia
nervosa, bulimia nervosa and BED, as eﬃcacy for
pharmacotherapy for EDNOS is largely unknown. It is
also acknowledged that the treatment of anorexia
nervosa is particularly poorly studied with rigorous
systematic reviews consistently concluding there is
little evidence for any therapy (e.g. Lock & Fitzpatrick,
2009). The major groups of antipsychotic, anti-
depressant, mood-stabilizing and anxiolytic agents are
presented ﬁrst, followed by less commonly used
agents and a discussion of issues in the management
of comorbid weight disorder. Comprehensive infor-
mation on medications used in the treatment of com-
plications of starvation and poor nutrition is found in
the text by Birmingham & Treasure (2010). Literature
for the present review was sourced from recent ex-
tensive searches conducted by either or both authors
for the purposes of Cochrane Library and Clinical
Evidence and other reviews (Claudino et al. 2006; Hay
& Claudino, 2010a, b ; Treasure et al. 2010; search date
2009) and updated to June 2010 for this report with a
Pubmed search using the terms ‘anorexia nervosa or
bulimia nervosa or BED and therapy or treatment’.
Also searched were reference lists of the following
systematic reviews: Brownley et al. 2007; Bulik et al.
2007 and Shapiro et al. 2007. Studies were selected for
inclusion, ﬁrst, if they met a level of evidence that
minimized risk of bias as in the above reviews, i.e.
were randomized controlled trials (RCTs) with com-
pletion rates at least 50%, or a systematic review of
RCTs. Second, we included studies of case series or
case reports or non-randomized trials where there
were no RCTs of an agent or where they were of rel-
evance in presaging RCTs. It should be noted that
these latter studies are at high risk of bias and should
be read as indicative of putative eﬀects and not as
substantive evidence of eﬃcacy.
Antipsychotic medications
Antipsychotic medication use is largely conﬁned to
people with anorexia nervosa. It is thought anti-
psychotics act by targeting dopaminergic and/or
serotinergic dysfunction (Connan & Stanley, 2003;
Kaye et al. 1999). Clinically, antipsychotics are used to
reduce extreme beliefs regarding body image and
eating-related disturbed thoughts such as intense ru-
minations about food, pseudo-hallucinations as well
as the hyper-arousal and agitation found when people
are confronted with weight gain (Powers & Santana,
2004 ; Taylor & McAskill, 2000). Paradoxically, in an-
orexia nervosa, they may not consistently promote
weight gain (McKnight & Park, 2010), despite this be-
ing a common side-eﬀect in normal weight people
with other psychiatric illnesses such as schizophrenia
(e.g. Chwastiak et al. 2009).
First-generation antipsychotics such as chlorpro-
mazine were found to cause severe adverse eﬀects
such as convulsions and Parkinsonism. In addition
as summarized in Table 1, there was inconsistent
evidence from RCTs regarding the eﬃcacy of tested
agents such as pimozide and sulpiride, in placebo-
controlled trials (Vandereycken, 1984 ; Vandereycken
& Pierloot, 1982). However, there have been a number
of promising trials of the second-generation anti-
psychotics olanzapine and quetiapine, following
case-series reports in all age groups by Bosanac et al.
(2005), Court et al. (2010), Duncan & del Dotto (2007),
Table 1. Main classes of medication use in anorexia nervosa tested in at least one randomized controlled trial (RCT)
Medication Clinical eﬀects RCT (n)
Antipsychotic
First generation
Pimozide Inconsistent vs. placebo 1
Sulpiride Inconsistent vs. placebo 1
Second generation
Amisulpride Greater weight gain vs. antidepressants 1
Olanzapine Greater reduction in ruminations vs. chlorpromazine 1
Greater weight gain and reduction psychological distress vs. placebo 2
Antidepressant
Amitriptyline Inconsistent greater weight gain vs. placebo 2
Clomipramine No signiﬁcant eﬀects vs. placebo 1
Fluoxetine Reduced relapse after weight gain vs. placebo 1
No reduced relapse after weight gain when added to cognitive behaviour
therapy vs. cognitive behaviour therapy
1
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Leggero et al. (2010) and Powers et al. (2007). In
these studies low doses (e.g. 1–5 mg/d olanzapine,
100–400 mg/d quetiapine) were commonly used.
There is also one case report supporting the use of
aripipazole in three patients with bulimia nervosa
as well as eight with anorexia nervosa (Trunko et al.
2010). In this series, the three patients with bulimia
nervosa had or previously had low weight. However,
there are few RCTs.
One RCT compared low-dose (50 mg/d) amisul-
pride (a D2 and D3 receptor antagonist at higher doses,
pre-synaptic antagonism at lower doses) to ﬂuoxetine
(mean dose 28 mg/d) and to clomipramine (mean
dose 57.69 mg/d) in 35 in-patients with anorexia
nervosa attending a weight restoration programme for
12 wk. Those given amisulpride had signiﬁcantly
greater weight gain but other illness features did not
diﬀer between groups (Ruggiero et al. 2001).
A systematic review (search date 2009) reported on
three RCTs testing olanzapine, a 5-HT2/D2 receptor
antagonist, vs. placebo or other antipsychotic for
anorexia nervosa (McKnight & Park, 2010). The ﬁrst
RCT compared it to chlorpromazine added to stan-
dard care in 15 anorexia nervosa patients (Mondraty
et al. 2005). In this trial (which was not blinded),
olanzapine (mean dose 10 mg/d) showed greater eﬃ-
cacy in reducing ‘anorexic ruminations’ compared to
50 mg/d chlorpromazine. Brambilla et al. (2007) com-
pared olanzapine (2.5 mg for 1 month, 5 mg for
2 months) to placebo as an adjunctive treatment
with cognitive behaviour psychotherapy (CBT) in
30 anorexia nervosa outpatients. Olanzapine was re-
ported to increase weight gain, and reduce depressive
symptoms and aggressiveness compared to placebo,
but only for patients of the binge-purge type. Finally,
Bissada et al. (2008) compared olanzapine combined
with a day-hospital treatment for 10 wk to placebo in
34 anorexia nervosa participants. Those taking olan-
zapine showed a greater rate of increase in weight
(achieving target BMI earlier) and improvement of
obsessive symptoms. While completion rates were
high (82%), 55% of eligible patients declined to be
randomized, indicating a potential problem of low
acceptance of olanzapine by people with anorexia
nervosa.
These few RCTs suggest a role for low-dose second-
generation antipsychotics in reducing psychological
distress particularly in the re-feeding phase of
anorexia nervosa treatment. However, there may be
problems with patient acceptance. Larger trials of
eﬃcacy are needed, particularly of quetiapine and
aripiprazole which may be less sedating and better
tolerated as they are putatively less likely to cause
severe weight gain feared by patients. At present there
are no trials of eﬃcacy in other eating disorders
and thus no speciﬁc indication for their use in recog-
nized guidelines (APA, 2006; NICE, 2004 ; RANZCP,
2004).
Antidepressants and like medications
In both anorexia nervosa and bulimia nervosa there is
putative rationale for the use of antidepressants. In
anorexia nervosa shared inheritance with depression
(Strober et al. 2000; Wade et al. 2000), neurobiological,
most notably serotonin dysfunction (Kaye et al. 1998,
2005) and concurrent depressive and obsessional psy-
chopathology (Godart et al. 2007; Kaye et al. 2004) have
suggested a role for antidepressant treatment. In
addition a recent meta-analysis (Lee & Lin, 2010) has
supported there being a speciﬁc genetic variant of the
serotonin transporter gene promoter found in people
with anorexia nervosa (but not bulimia nervosa).
Similarly, there are high rates, up to 50%, of lifetime
comorbid depression and bulimia nervosa (Hudson
et al. 2007). However, the eﬃcacy of antidepressant
treatment in bulimia nervosa appears independent
of eﬀects on mood and is more likely related to
augmentation of satiety mechanisms and subsequent
reduction in binge eating (see below) (Goldstein et al.
1999; Walsh et al. 2000).
Claudino et al. (2006) conducted a systematic review
of eﬃcacy of antidepressants in acute phase anorexia
nervosa. Only four small RCTs were identiﬁed, three
of the tricyclic antidepressants (TCAs) amitriptyline
(Biederman, et al. 1985; Halmi, et al. 1986) and clomi-
pramine (Lacey & Crisp, 1980), and one of the selective
serotonin reuptake inhibitor (SSRI) ﬂuoxetine (Attia
et al. 1998). Halmi et al. (1986) randomized 72 in-
patients to amitriptyline, cyproheptadine or placebo
treatment groups. They reported a small statistically
signiﬁcant eﬀect in decreasing the time to achieve tar-
get weight for both drug groups. The three other
acute-phase trials found no signiﬁcant diﬀerences in
symptom response or weight gain between active and
placebo groups. In addition, cardiovascular risk with
tricyclic drugs limits their use in this patient group
(Biederman et al. 1985; Halmi et al. 1986). While the
doses of antidepressant used in these trials were low
and the duration of treatment was short, the consist-
ency of negative ﬁndings does not provide support
for their use. There is little evidence for other classes
of antidepressants, although a case report for mirta-
zepine (which has noradrenergic and serotonergic
activity) is promising. In this report mirtazepine aided
weight gain and mood in a 50-yr-old woman with a
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history of food restriction since her adolescence (Safer
et al. 2011).
It has been postulated that the lack of eﬃcacy of
serotonergic drugs in the acute phase of anorexia
nervosa may be related to low levels of serotonin
metabolites in cerebrospinal ﬂuid (e.g. as found by
Jimerson et al. 1992) due to poor dietary intake of
the serotonin precursor tryptophan. However, a small
RCT that compared ﬂuoxetine+nutritional sup-
plements with ﬂuoxetine+ ‘placebo nutritional sup-
plements’ found that the former did not improve
the physiological eﬀects of chronic under-nutrition or
appear to enhance the eﬃcacy of drugs (Barbarich et al.
2003). More recent ﬁndings using positron emission
tomography (PET) imaging by Bailer et al. (2007) sug-
gest that there may be a better response to medication
for those with restricting type anorexia vs. those
with bulimic type because of a diﬀerential serotonin
receptor-binding activity. A body of work summar-
ized in Kaye (2008) now supports the view that there is
a poor response to antidepressants because of adverse
eﬀects of starvation in the 5-HT1A receptor and in ex-
tracellular 5-HT concentrations.
Two double-blind RCTs have tested ﬂuoxetine for
patients following acute treatment weight restoration
(Kaye et al. 2001; Walsh et al. 2006). The ﬁrst small trial
(n=35) found signiﬁcantly more patients on ﬂuoxetine
had reduced relapse, namely, they maintained an ad-
equate weight and symptom reduction during the 1-yr
follow-up after hospital discharge compared to the
control group. However, attrition was very high in the
placebo group (84% vs. 37% in the treatment group),
and for most the decision to terminate the study was
based on symptoms indicating a relapse. A second
larger trial of 93 patients (Walsh et al. 2006) did
not ﬁnd adding ﬂuoxetine to CBT helped prevent
relapse (deﬁned as BMI falling toj16.5 kg/m2 and/or
worsening of anorexic symptoms, development of
major clinical problems or suicidal ideation). In ad-
dition a well-designed RCT (n=122 randomized;
Halmi et al. 2005) was inconclusive as there was an
unacceptably high rate of attrition (73%) in partici-
pants randomized to a ﬂuoxetine (60 mg/d) arm
compared to CBT arm (57% attrition) or combination
arm (59%). Thus, antidepressant use is supported
neither in the acute nor maintenance phases of anor-
exia nervosa treatment.
The situation is very diﬀerent for use of anti-
depressants in bulimia nervosa where there are a
number of RCTs (see Table 2), systematic reviews
and meta-analyses that have consistently supported
a range of classes of agents, namely TCAs, SSRIs and
monoamine oxidase inhibitors (MAOIs) in reducing
binge eating and vomiting and improving mood and
anxiety symptoms (Bacaltchuk & Hay, 2003 ; Hay &
Claudino, 2010a). Speciﬁc SSRIs evaluated include
ﬂuoxetine, citalopram, sertraline and ﬂuvoxamine.
In Bacaltchuk & Hay (2003) pooled data from 24
RCTs found that bulimic behaviours had reduced by
up to 70% in the short-term (mean 8 wk) ; however,
pooled abstinence rates were less than 20% when
antidepressants were used without any concurrent
psychosocial intervention. Moreover, Agras et al.
(1992) found that one-third of the 25% of patients who
were abstinent at the end of treatment relapsed
over time. In contrast, a small number of relapse-
prevention studies have reported an eﬀect of continu-
ing pharmacotherapy (Fichter et al. 1996; Romano et al.
2002), although these ﬁndings should be viewed
with caution due to high attrition (around 90% at 1 yr
follow-up in Romano et al. 2002).
Attrition is also high in most trials (around 40%) of
single pharmacological treatments, in part because
of side-eﬀects but also probable patient preference for
non-pharmacological therapies. There does, however,
appear to be better acceptability for SSRIs. This may be
because of their short-term eﬀects on reduction in
appetite and weight, and the use of ﬂuoxetine has
superseded TCAs (Fichter et al. 1991; Fluoxetine
Bulimia Nervosa Collaborative Study Group, 1992;
Goldstein et al. 1999; Romano et al. 2002). The SSRI
antidepressant, ﬂuoxetine, is thus the only medication
recommended by leading guidelines for bulimia
nervosa (APA, 2006), and it is at a high dose of
60 mg/d. Lower doses were less eﬃcacious in this
patient group (Fluoxetine Bulimia Nervosa Col-
laborative Study Group, 1992 ; Goldstein et al. 1995).
Clinicians may note that further analyses of these
two studies by Sysko et al. (2010) reported attaining
early response (more than 60% reduction in binge
eating or vomiting frequency in the ﬁrst 3 wk of
treatment) was strongly predictive of eventual treat-
ment response.
Strong evidence of the eﬃcacy of other SSRI agents
is still lacking, but in clinical practice they may be
considered for patients that do not respond well to
ﬂuoxetine. There are three similar and very small
randomized placebo-controlled trials of citalopram
(Milano et al. 2005a), sertraline (Milano et al. 2004), and
ﬂuvoxamine (Milano et al. 2005b), which were sup-
portive for eﬃcacy of all three SSRIs. In addition, a
small (n=27) single blinded trial comparing ﬂuoxetine
and citalopram found no diﬀerences in outcomes, but
the attrition rate wasmoderately high (Leombruni et al.
2006). However, a later study from the same group
(Giaquinto et al. 2006) compared the three SSRIs in the
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treatment of bulimia nervosa and found sertraline
(100 mg/d) associated with a very small reduction in
binge eating and purging compared to ﬂuvoxamine or
ﬂuoxetine. Finally, as shown on Table 2, most agents
only have one RCT published and it is also likely there
is publication bias (Bacaltchuk & Hay, 2003). A large
(n=300) negative trial of 150–300 mg ﬂuvoxamine
remains published only in secondary reports (Corcos
et al. 1996; Freeman, 1998).
Inconclusive and lower levels of evidence are
available with drugs that act on the noradrenergic
system. Based on ﬁndings from earlier studies that
tested drugs with noradrenergic eﬀects, on the
involvement of the noradrenergic system in the regu-
lation of hunger and satiety, and on existing con-
nections between serotonergic and noradrenergic
pathways in the central nervous system, two small
uncontrolled trials of reboxetine, a selective nora-
drenaline reuptake inhibitor, have reported positive
ﬁndings (El-Giamal et al. 2000; Fassino et al. 2004). Two
small uncontrolled studies of milnacipran, a selective
serotonin and noradrenaline reuptake inhibitor, have
suggested a trend towards reduction binge eating
(El-Giamal et al. 2003; Noma et al. 2008).
Finally, bupropion is an antidepressant that blocks
reuptake of noradrenaline and dopamine. It was
Table 2.Main classes of medication use in bulimia nervosa tested in at least one randomized controlled trial (RCT)
Medication Clinical eﬀects RCT (n)
Tricyclic antidepressants
Imipramine Bulimic symptom reduction vs. placebo 1
Less reduction binge eating vs. cognitive behaviour
therapy (CBT) and less reduction binge eating vs.
combined CBT and imipramine and no signiﬁcant
diﬀerence when combined with CBT vs. CBT alone
1
Desipramine Symptom reduction vs. placebo 2
No signiﬁcant symptom reduction vs. CBT and
no reduction binge eating vs. combined CBT
and desipramine and no signiﬁcant diﬀerence
when combined with CBT vs. CBT alone
1
Monoamine oxidase inhibitors
Phenylzine, Bulimic symptom reduction vs. placebo 2
Isocarboxacid Bulimic symptom reduction vs. placebo 1
Brofaromine Bulimic symptom reduction vs. placebo 1
Moclobemide Bulimic symptom reduction vs. placebo 1
Selective serotonin reuptake inhibitors
Fluoxetine Reduced bulimic symptoms at 60 (but not 20)mg/d vs. placebo 3
Reduced relapse but high attrition at 60 mg/d vs. placebo 1
No signiﬁcant diﬀerences in outcome vs. CBT and no
reduction binge eating vs. combined CBT and ﬂuoxetine
and no signiﬁcant diﬀerence when combined with
CBT vs. CBT alone or nutritional counselling
3
No diﬀerences in outcome vs. citalopram 1
Citalopram Reduced bulimic symptoms vs. placebo 1
Sertraline Reduced bulimic symptoms vs. placebo 1
Poorer reduction in symptom vs. ﬂuvoxamine or ﬂuoxetine 1
Fluvoxamine Reduced bulimic symptoms vs. placebo 1
Reduced relapse at 150 mg/d vs. placebo 1
Other
Mianserin Bulimic symptom reduction vs. placebo 1
Trazodone Bulimic symptom reduction vs. placebo 1
Bupropion Reduced bulimic symptoms vs. placebo but high
seizure rates preclude its use
1
Topiramate Reduced bulimic symptoms and greater weight loss vs. placebo 2
Naltrexone Inconsistent reduction bulimic symptoms vs. placebo 2
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found superior to placebo at reducing binge eating
and purging episodes in one trial of 55 bulimia
nervosa participants (Horne et al. 1988). However, it is
contraindicated for people with bulimia nervosa due
to the high rates (7.2%) of generalized tonic-clonic
seizures found in this RCT.
There have been a number of RCTs comparing an-
tidepressants in combination with CBT (the present
ﬁrst-line treatment for bulimia nervosa ; APA, 2006;
NICE, 2004) with inconsistent results. When pooled in
meta-analyses (Bacaltchuk et al. 2001; NICE, 2004)
ﬁndings suggest that (a) drug-alone treatments have
consistently less eﬃcacious binge-eating abstinence
rates than when combined with CBT, and (b) dropout
rates in the antidepressant arms of such trials are high
(more than 50% in some studies).
Antidepressants are considered to have a role in the
treatment of BED based on their eﬃcacy in reducing
binge-eating in patients with bulimia nervosa
(Bacaltchuk & Hay, 2003) and on the high rate of co-
morbid major depressive disorder in patients with
BED (Fontenelle et al. 2003; Javaras et al. 2008). As
shown on Table 3, two TCAs [imipramine (Laederach-
Hofmann et al. 1999) and desipramine (Agras et al.
1994)] and several SSRIs, such as ﬂuvoxamine, sertra-
line, ﬂuoxetine and citalopram (Arnold et al. 2002;
Devlin et al. 2005; Grilo et al. 2005a ; Hudson et al. 1998;
McElroy et al. 2000, 2003a, b ; Pearlstein et al. 2003) have
been evaluated in RCTs of BED. These trials have been
small (n=85 or fewer), and most short-term (mean
duration of 10 wk, all <20 wk) (Claudino et al. 2010).
Early trials reported consistent reductions in binge-
eating frequency but more recently two trials with a
longer duration of 16–20 wk that compared ﬂuoxetine
to placebo (Devlin et al. 2005; Grilo et al. 2005a) found
ﬂuoxetine ineﬀective in reducing binge eating or
weight.
Stefano et al. (2008) reported a meta-analysis of
seven pooled studies (six with SSRIs and one with
imipramine) involving a total of 300 patients, whereby
there was greater remission of binge-eating episodes
at the end of trials in the groups that received anti-
depressants compared to the placebo groups (40.5%
vs. 22.2%). Another meta-analysis (Reas & Grilo, 2008)
found SSRIs were associated with signiﬁcantly in-
creased binge-eating remission rates compared to
placebo (n=335, n=7 studies, RR 0.81, 95% CI
0.70–0.94) indicating that non-remission rates are re-
duced by 19% with this class of antidepressant.
With regard to overweight problems, a common
and problematic comorbidity, weight loss has been
modest in most studies and no diﬀerences in weight
Table 3.Main classes of medication usea in binge-eating disorder (BED) tested in at least one randomized controlled trial (RCT)
Medication Clinical eﬀects RCT (n)
Tricyclic antidepressants
Imipramine BED symptom and weight reduction combined with dietary counseling vs.
placebo and dietary counselling
1
Desipramine No greater BED symptom reduction or weight loss when combined with
cognitive behaviour therapy (CBT) and behavioural weight loss (BWL)
1
Selective serotonin reuptake inhibitors
Fluoxetine Inconsistent reduced binge eating and improved weight control vs. placebo 2
Less BED symptom reduction but not less weight loss vs. ﬂuoxetine+CBT 1
Citalopram Reduced binge eating and improved weight control vs. placebo 1
Sertraline Reduced binge eating and improved weight control vs. placebo 1
Fluvoxamine Inconsistent reduced binge eating and improved weight vs. placebo 2
Escitalopram No signiﬁcant reduction binge eating but improved weight vs. placebo 1
Other
Atomoxetine BED symptom and weight reduction vs. placebo 1
Topiramate Reduced BED symptoms and greater weight loss vs. placebo 2
When combined with CBT reduced BED symptoms and weight vs.
CBT alone
1
Zonisamide Reduced bulimic symptoms and greater weight loss vs. placebo 1
Orlistat When combined with BWL or guided self-help CBT reduced BED symptoms
and greater weight loss vs. placebo
2
a Sibutamine has not been included here because of safety concerns and its subsequent withdrawal from the market in North
America, Europe and other countries including Australia in 2010.
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loss were found in the meta-analysis of Stefano et al.
(2008). Reas & Grilo (2008) reported a modest eﬀect on
weight loss with SSRIs compared to placebo in meta-
analysis. One trial of sertraline was found to lead to
clinically signiﬁcant weight loss : 50–200 mg/d sertra-
line (mean loss 5.4 kg in 6 wk) (McElroy et al. 2000).
Only citalopram (McElroy et al. 2003a, b) has been
found to have a greater eﬃcacy in reducing depressive
symptoms than placebo in studies, but most trials
have included patients with low baseline scores in
depression scales (Appolinario & McElroy, 2004).
More recently, escitalopram (mean dose 25.5 mg/d) in
a RCT was associated with greater weight loss than in
the placebo group, but eﬀects on binge remission were
weaker (Guerdjikova et al. 2008).
Venlafaxine, a selective serotonin and noradrenaline
reuptake inhibitor, has been tested in only an uncon-
trolled open trial of 35 obese/overweight patients with
BED. Results showed a signiﬁcant reduction in binge-
eating episodes and weight (Malhotra et al. 2002). One
case study has also reported good eﬀects for dulox-
etine (another combined serotonin and noradrenalin
reuptake inhibitor) in a patient with treatment-
refractory BED (Bernardi & Pallanti, 2010). RCTs are
needed to evaluate the eﬃcacy of these agents.
Some agents with pharmacological actions similar
to antidepressants have been trialed in BED. A short,
placebo-controlled RCT tested atomoxetine, a highly
selective norepinephrine reuptake inhibitor with
weight loss properties, in 40 obese patients with BED.
Atomoxetine was associated with greater improve-
ment in binge-eating behaviours and weight loss and
was reasonably tolerated (McElroy et al. 2007a), but to
date these ﬁndings have not been replicated.
Sibutramine is an anti-obesity agent that is a selec-
tive serotonin and noradrenaline inhibitor that may
induce weight loss by enhancing satiety and prevent-
ing the fall in energy expenditure that usually follows
weight loss. Sibutramine at a dose of 15 mg/d has
been tested against placebo in two 12-wk RCTs
(Appolinario et al. 2003; Milano et al. 2005c) and one
24-wk trial (Wilﬂey et al. 2008) of BED. In these trials
and a meta-analysis (Reas & Grilo, 2008) sibutramine
was associated with signiﬁcantly reduced binge eating
and weight loss compared to placebo. However,
attrition was high (Wilﬂey et al. 2008), a high placebo
response (also found by e.g. Pearlstein et al. 2003)
was noted, and those more likely to have a placebo
response had less severe symptoms at baseline
(Jacobs-Pilipski et al. 2007). More importantly, safety
issues related to increased cardiovascular events in
obese people with high cardiovascular risk have been
reported (James et al. 2010) and in 2010 sibutramine
was withdrawn from the market in the USA, Europe
and other countries.
RCTs of combination approaches of antidepressants
with CBT have suggested little advantage over CBT
alone in reducing binge eating (Agras et al. 1994;
Devlin et al. 2005; Grilo et al. 2005a), but there may be
positive eﬀects for increased weight loss beyond the
eﬀects of psychotherapy (Agras et al. 1994; Laederach-
Hofmann et al. 1999) or antidepressants alone (Ricca
et al. 2001). Two recent combination trials, which lasted
16 wk (Grilo et al. 2005a) and 20 wk (Devlin et al. 2005),
used a four-cell design to compare CBT+ﬂuoxetine,
CBT+placebo, ﬂuoxetine, and placebo. These studies
did not report any increase of treatment eﬃcacy when
ﬂuoxetine was added to CBT. However, when eating
psychopathologies were analysed, results were better
in the groups treated with CBT than in the groups
treated only with drugs. For example, greater binge
remission (but not greater weight loss) was found
in the group treated with ﬂuoxetine and CBT than in
the one treated with medication alone (Grilo et al.
2005a).
Mood-stabilizing agents
Mood-stabilizing agents such as lithium and antic-
onvulsant drugs have not had a large role in the
treatment of eating disorders. A very small (n=16)
placebo-controlled RCT of lithium treatment (mean
plasma level 1.0¡0.1 mequiv./1) in acute-phase an-
orexia nervosa was supportive of greater weight gain
in the active group (Gross et al. 1981). However, this
early study was never followed by more substantive
trials. Of more contemporary interest are antic-
onvulsant drugs such as topiramate, which have been
studied in a range of mental health conditions
(Arnone, 2005) and been considered to be possibly
useful in eating disorders for their anti-impulsivity
and weight-losing eﬀects (Ben-Menachem et al. 2003;
Li et al. 2005; McElroy et al. 2007b).
Following promising case series (Barbee, 2003) a
double-blind, placebo-controlled RCT has supported
the eﬃcacy of topiramate (Hedges et al. 2003a ; Hoopes
et al. 2003b) for bulimia nervosa patients. In this trial,
those treated with topiramate had signiﬁcantly greater
reductions in mean weekly binge and/or purge days
than those on placebo (44.8% vs. 10.7% for placebo)
and also greater weight loss with topiramate (1.8 kg,
compared to the placebo group mean increase of
0.2 kg). Nickel et al. (2005) also found that topiramate
(250 mg/d) over a 10-wk period signiﬁcantly reduced
binge/purge frequency, weight and improved health-
related quality of life compared to a placebo condition
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in 60 participants. However, although reportedly
well tolerated, many patients in the topiramate arm
experienced cognitive impairment and neurological
symptoms such as paresthesia. Other problems in-
clude the report of very high congenital malformation
rates in women taking topiramate for epilepsy, which
may limit its acceptability and use in young women
with eating disorders (Hunt et al. 2008).
Two double-blind RCTs have tested topiramate
against placebo in obese patients with BED. The
ﬁrst study enrolled 61 subjects for a 14-wk treatment
(median dose 213 mg/d) (McElroy et al. 2003b). The
second larger multi-centre trial (McElroy et al. 2007b)
with 394 patients lasted 16 wk and used a median dose
of 300 mg/d. In these two trials, topiramate reduced
binge frequency, increased binge remission and
weight loss, and improved psychological comorbidity.
Longer-term eﬃcacy of topiramate was tested in a
42-wk, open-label extension (McElroy et al. 2004) of
the ﬁrst trial with 35 patients. Patients maintained
reduced binge-eating frequency and weight loss in the
subsequent open phase, and patients on placebo also
showed improvements when given topiramate in the
open phase. However, this study had high attrition
and adverse eﬀects during the two phases, possibly
because of the rapid increase of doses and the in-
clusion of patients with psychiatric comorbidity
(McElroy et al. 2003b, 2004).
One RCT (McElroy et al. 2006) has compared an-
other anticonvulsant zonisamide (mean endpoint
dose of 436 mg/d over 16 wk) to placebo in 60 obese
women with BED. Although it was more eﬀective than
placebo in reducing binge-eating frequency and
weight, zonisamide had considerable side-eﬀects
and was poorly tolerated. An open trial over 1 yr of
52 patients (30 with sub-threshold disorder) also re-
ported an advantage in binge-eating reduction and
weight loss when zonisamide was added to CBT
(Ricca et al. 2009). However, attrition was high (50%)
in the drug-treated group. In a meta-analysis (Reas
& Grilo, 2008) of results from anti-epileptic trials
(n=515) (McElroy et al. 2003a, b, 2006, 2007a, b), large
eﬀects were reported for binge remission and weight
loss (RR 0.63, 95% CI 0.51–0.78 ; WMD x4.6 kg, 95%
CIx5.36 tox3.79, respectively) with a non-remission
risk reduction of 37%.
Finally a double-blind, multicentre RCT compared
the eﬀects of topiramate (mean dose of 206 mg/d)
with placebo when combined with CBT in 73 patients
with BED. Those in the combined drug and CBT arm
had higher rates of binge-eating remission (83.8% vs.
61.1%) and weight loss (x6.8 kg vs. x0.9 kg) in the
21 wk compared to the CBT-alone arm (Claudino et al.
2007). Adverse eﬀects were, however, more common
in the topiramate group.
Anxiolytic and other agents
Anxiolytic drugs such as benzodiazepines are some-
times used in anorexia nervosa (de Zwann & Roerig,
2003) but there are no RCTs testing their use.
Steinglass et al. (2007) tested D-cycloserine (a gluta-
mate partial agonist) in a very small study of 14 pa-
tients (nine with anorexia nervosa) which was part of
evaluating an exposure (to food) therapy. Results were
mixed and food intake was not enhanced.
The opiate antagonist naltrexone has been trialled in
eating disorders based on the premise that some eat-
ing-disorder behaviours (specially binge eating) are
‘addictive-like’ behaviours. Results of clinical trials
with naltrexone in bulimia nervosa are conﬂicting.
Mitchell et al. (1989) reported negative results in
their low-dose naltrexone cross-over study with 16
normal-weight women with bulimia nervosa, whereas
Marrazzi et al. (1995a) found signiﬁcant reductions in
binge/purge symptoms during naltrexone treatment
in all patients (n=19) with bulimic symptoms
(anorexia nervosa of the bulimic subtype or bulimia
nervosa) in a double-blind placebo, cross-over study.
Experimental studies suggest naloxone, also an opioid
antagonist, may have a role in reducing binge eating in
BED (Drewnowski et al. 1995; Marrazzi et al. 1995b)
but there are no RCTs as yet. Baclofen, a centrally act-
ing c-amino-butyric acid B (GABA-B) receptor agonist
has also shown promise in reducing binge eating at
60 mg/d in a small case series (Broft et al. 2007).
Increasing evidence suggests that the ventromedial
and lateral regions of the hypothalamus and the
arcuate nucleus play a signiﬁcant role in the regulation
of appetite, and it argues high levels of glutamate
may lead to appetite dysregulation through glutamate-
induced neurotoxic eﬀects mediated by N-methyl-
D-aspartate (NMDA) receptors (Hermanussen &
Tresguerres, 2003). Memantine is a low-to-moderate-
aﬃnity non-competitive NMDA receptor antagonist
that in one open-label trial of 16 overweight BED
participants (Brennan et al. 2008; ﬂexible dose of
5–20 mg/d) decreased binge-eating frequency and
obsessive features of binge eating, but not weight.
Anti-obesity agents
The high rates of comorbidity of obesity and BED has
lead to interest in the use of anti-obesity agents in this
group. Their use is supported by two factors : their
eﬀects on the reduction of appetite or increase in
216 P. J. Hay and A. M. Claudino






satiety, thus their possible eﬀects on binge-eating
behaviours, and their promotion ofweight loss, as BED
is frequently associated with obesity or overweight
(Appolinario & McElroy, 2004).
Sibutramine, a selective serotonin and noradrena-
line inhibitor has been discussed above. Two RCTs
have tested the use of orlistat, a lipase inhibitor,
against placebo, in combination with a mildly
reduced-calorie diet of 24 wk (89 obese patients with
BED) (Golay et al. 2005) or combined to a CBT-based
guided self-help manual for 12 wk (50 patients)
(Grilo et al. 2005b). After 24 wk, patients taking orlistat
showed greater mean weight loss (x7.4% vs.x2.3%)
as well as a greater reduction of eating-disorder
symptoms, compared to those taking placebo (Golay
et al. 2005). Grilo et al. (2005b) reported better results in
the orlistat group for both, binge remission (64% vs.
36%) and clinically signiﬁcant weight loss (>5% from
baseline weight : 36% vs. 8%), although only weight
loss was kept at the 3-month follow-up.
A recent meta-analysis of comparative eﬀect sizes
for treatments of BED combined results of 38 studies
of RCTs and uncontrolled studies and pooled all types
of pharmacotherapy, as well as psychotherapies in
computing comparative eﬀect sizes (Vocks et al. 2010).
The paper supported the above ﬁndings, namely sig-
niﬁcant albeit modest eﬀect sizes of 1.19 (95% CI
0.88–1.49, 11 studies, 212 participants) for binge-eating
reduction and for weight loss 0.50 (95% CI 0.15–0.85,
three studies, 77 participants) but less impact on
changes in eating-disorder cognitions. Psychotherapy
had larger eﬀect sizes supporting it as ‘ﬁrst-line’
treatment over pharmacotherapy. However, the
analysis was problematical in that diﬀerent forms
of both psychotherapy and pharmacotherapy were
pooled.
Conclusions
Psychotherapies such as CBT or family therapy
are treatments of choice for eating disorders but
pharmacotherapies have an important role in speciﬁc
disorders, albeit with a moderate to weak evidence
base. Strongest evidence is for antidepressants, par-
ticularly high-dose ﬂuoxetine in bulimia nervosa, and
anticonvulsants (topiramate) or anti-obesity agents
(sibutramine) for BED. In addition, attrition rates are
usually higher than for psychotherapies. Low-dose
antipsychotic medication may be clinically useful as
adjunct treatment in acute anorexia, particularly
where there is high anxiety and obsessive eating-
related ruminations and failure to engage, but more
trials are needed. Drug therapies such as topiramate
and anti-obesity medication may aid weight loss in
obese or overweight patients with BED; however,
common or potentially serious adverse eﬀects limit
their use and it is thought the placebo response may be
high in this disorder.
The mechanisms of eﬀects of pharmacological
therapies in eating disorders also need further
study. While putative action is through modulation of
dopamine and serotonin, central pathway regulation
of other neurotransmitters such as noradrenaline also
occurs. This is a developing ﬁeld as exempliﬁed by
Kaye and colleagues (Kaye, 2008) whose work has
found limbic system dopaminergic dysregulation that
persists after anorexia nervosa recovery and Frieling
et al. (2010) who propose a new hypothesis of dopa-
minergic (dys-) regulation, namely that a hyperdopa-
minergic state in acutely ill anorexia nervosa leads to
counter-regulatory mechanisms that in recovery result
in reduced dopaminergic activity. Kaye and collea-
gues (2008) also postulate in an inherent serotonergic
dysregulation that contributes to a dysphoria which
is partially relieved by food restriction, albeit that
the malnourished state impedes the biological
activity of serotonergic antidepressants. Studies of
antidepressant use in bulimia nervosa also support
speciﬁc actions on satiety separate to mood modu-
lation, and future research elucidating mechanisms of
action will help guide more rationale developments in
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